Close Menu

NEW YORK – CareDx reported on Monday that its preliminary revenues for the fourth quarter of 2019 are expected to be $35.7 million to $36.0 million, an increase of 52 percent to 53 percent compared to the $23.5 million in revenues reported in Q4 2018. Analysts expect the company to report $34.2 million in revenues for Q4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.